bpc 157 lyme disease A Functional Medicine Guide to bpc 157 lyme disease BPC-157

Moderate risk individuals include those over 40 with minor family history, those slightly behind on screening, or those using BPC-157 for moderate rather than severe healing needs

You've got a win

Initial treatment for patients with neurological involvement follows British National Formulary (BNF) guidance: Hydroxocobalamin 1 mg intramuscularly on alternate days for approximately 2-3 weeks (or until no further improvement) Maintenance therapy then consists of hydroxocobalamin 1 mg intramuscularly every two months Hydroxocobalamin is preferred over cyanocobalamin in the UK due to superior retention and fewer injections required

The most likely range of outcomes, based on how analogous FDA processes have unfolded historically, is somewhere between "some peptides moved to a more permissive category, others kept on the restricted list pending further data" and "all peptides kept on the restricted list pending further data, with specific data requests for each." A blanket lifting of all restrictions is the least likely outcome and would be an unusual departure from how the agency typically handles incomplete safety data

Proper usage guidelines can help maximize potential benefits while minimizing risks